Genmab — September 2019
-
Lige mht. timingen for partnerskabsaftaler, så forbeholder jeg mig retten til at være skeptisk
-
"Then, the important issue is that we treat as many patients [as we can] with daratumumab in the first-line setting. This is the priority." https://www.onclive.com/conference-coverage/imw-2019/daratumumabvtd-regimen-shows-benefit-in-newly-diagnosed-highrisk-multiple-myeloma
-
Enig Solsen
-
-
BryanGarnier again GENMAB - BUY | DKK1500 vs. DKK1450 (+9%)
Ofatumumab: an additional option for patients more than an Ocrevus’ killer?At first glance, efficacy seems in line with Ocrevus
Could patients prefer ofatumumab’s at-home dosing?
In other news, Darzalex further expand its grip in MM -
-
-
-
By comparison, ofatumumab can be self-injected by a patient at home every four weeks. Bar-Zohar is keen to point out that just one of the 1882 patients enrolled into the ASCLEPIOS study programme was forced to discontinue ofatumumab therapy due to an injection-related side effect.
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind